# Last steps towards a potential therapy against intestinal worms

## The culmination of 10+ years of research

At the STOP2030 research project, we aim to accelerate the implementation of an innovative treatment against soil-transmitted helminth (STH) infections.

Our **novel drug combination** is a **safe**, **accessible and affordable** alternative to available treatments that helps overcome current limitations. In this project, our goal is to take the final steps towards the approval of this co-formulation, and assist in the development of the regulatory and supply pathways needed to **support its integration** in disease control plans.

STOP2030 is the result of years of research and work in previous projects and clinical trials. With this final **public-private collaboration** between pharma, clinicians, and advocacy professionals, we aim to provide a solution that reaches communities and complements existing control measures, **driving us closer to disease control**.

# The project in numbers





**Years** 

## **Countries**

Partners



Funding



# Our Consortium

An African and European partnership towards disease control



# **Find out more**



O

**STOP 2030** 





# Co-funded by the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement **No 10110308** 

#### Funded by

@stop2030project



Federal department of Economic Affairs, Education and Research EAER State Secretariat for Education, Research and Innovation SERI

Swiss Confederation

# Intestinal worms, a long story of unmet needs

### Infecting a guarter of the world's population



Soil-transmitted helminth (STH) infections affect children and adults in the world's poorest communities. They mostly impact growth and development of children, sometimes causing anaemia and life threatening complications.



Health and social impact of STH

.5 Billion

People Infected

Beyond their health concerns, these infections cause a huge disease burden in affected communities. The massive loss in work and school days due to these diseases affects the whole country's economy and development.

000

0 00

**1.9 Million** 

life years

Disability adjusted

## A call for a better treatment

Currently, STH infections are addressed only by single-drug therapies using benzimidazoles or ivermectin that have several **limitations** for the control of the disease:



Not effective against all helminth species: Two species are not susceptible to treatment by benzimidazoles.

**Risk of emergence of resistance:** 

Already reported in some species.





Insufficient to reach elimination objectives: Set at <2% prevalence of infections in children.

## **Current therapeutic approach**



Benzimidazoles

vermectin



Roundworm Ascaris lumbricoides



Whipworm Trichuris trichiura

Hookworm Hookworm Ancylostoma



duodenale



Strongyloides

stercoralis

**Benzimidazoles** resistant



# **Simplifying treatment** through combination

A new approach to reach international objectives

Our co-formulation is based on two already licensed drugs that are widely-used as anthelmintics around the world. This combination overcomes the limitations of current treatments:



Effective against all species: Including Strongyloides stercoralis and Trichuris trichiura



Minimises the risk of resistances: By using drugs with different mechanisms of action



**Developed along regulatory** and supply pathways: To foster implementation by health agencies

## **Discover our background**

Browse through the publications repository of our prior STOP projects



